Combined radiochemotherapy with Temozolomide for glioblastoma

The study by Roger Stupp et al.1, published in NEJM in 2005, is considered the basis of current treatment for glioblastoma. It demonstrated for the first time that combined radiochemotherapy with Temozolomide provides a significant and clinically relevant survival benefit in the treatment of glioblastoma.

Stupp survival in glioblastoma
Survival time comparing radiotherapy alone with combined radiotherapy and Temozolomid (Stupp regimen). Figure adapted from Stupp et al. 2005.

References


    Editorial transparency

    Authorship & revisions

    Who created and updated this article, and which changes are documented.

    Article created by
    Last edited:
    on
    Revision history
    4 edits · 1 contributor
    Author list:
    Show revision history 4 entries

    4 edits by 1 author

    Edit · Alaric Steinmetz · (+1 −1)

    No content change recorded

    Edit · Alaric Steinmetz ·

    No content change recorded

    Edit · Alaric Steinmetz · (+4 −4)
    • Text changed: “The 2005 study by Roger Stupp et al.[^1], published in the NEJM, is considered the basis of current treatment for [glioblastoma](\/neurochirurgische-krankheitsbilder\/glioblastom). It demonstrated for the first time that combined radiochemotherapy with Temozolomide provides a significant and clinically relevant survival benefit in the treatment of glioblastoma.”“The study by Roger Stupp et al.[^1], published in NEJM in 2005, is considered the basis of current treatment for [glioblastoma](\/neurochirurgische-krankheitsbilder\/glioblastom). It demonstrated for the first time that combined radiochemotherapy with Temozolomide provides a significant and clinically relevant survival benefit in the treatment of glioblastoma.”

    Article created on · Alaric Steinmetz

    Image viewer

    Image

    Open original